The US and Canada have healthcare, life science and medical device industries that are complex and interconnected.

On March 6, President Donald Trump instituted a 25 percent ad valorem rate of duty on goods imported from Canada under the International Emergency Economic Powers Act.[1] The tariffs will not be implemented on goods that comply with the United States-MexicoCanada Agreement until April 2.[2] In turn, Canada has announced a $155 billion tariff package on the US.[3]

Download the full Law360 article, "Mitigating Tariff Risks For Healthcare In US And Canada."



Contacts

Jeff Wurzburg
Jeff Wurzburg
Partner
Email
jeff.wurzburg@nortonrosefulbright.com
T: +1 210 270 9338
Vanessa Grant
Vanessa Grant
Senior Partner
Email
vanessa.grant@nortonrosefulbright.com
T: +1 416 216 4056

Practice areas:

Industry:

Recent publications

IAR-Issue-22_Assests_Website-hero

Publication

International arbitration report

Our 23rd report spotlights landmark legislative reforms such as the UK’s new Arbitration Act 2025 and South Africa’s rise as a regional arbitration hub. We examine procedural innovations, enforcement challenges, and the evolving role of tribunals in promoting settlement.

Global | July 24, 2025

International arbitration
Unlocking the potential of arbitration in cross-border insolvency disputes- SIAC’s proposal

Publication

Unlocking the potential of arbitration in cross-border insolvency disputes: SIAC’s proposal

We examine the key elements of SIAC’s draft Insolvency Arbitration Protocol (SIAC Draft Protocol).

Global | July 24, 2025

International arbitration
The new Arbitration Act 2025- Necessary

Publication

The new Arbitration Act 2025: Necessary modernization or missed opportunity?

The Arbitration Act 2025 (the 2025 Act) received Royal Assent on February 24, 2025.

Global | July 24, 2025

International arbitration
Site search

Subscribe and stay up to date with the latest legal news, information and events . . .

Register now